BiologicalDrug
Gebasaxturev clinical trials
Also written CAVATAK, CVA21, Coxsackievirus A21 and CAV21.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Brand
Other names
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
Viralytics (10) · Merck Sharp & Dohme LLC (2) · Olivia Newton-John Cancer Research Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Gebasaxturev is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)TerminatedPhase 1/2Merck Sharp & Dohme LLCNCT04521621Written as Gebasaxturev
- Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)TerminatedPhase 2Merck Sharp & Dohme LLCNCT04152863Written as Gebasaxturev IV
- CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)CompletedPhase 1ViralyticsNCT02043665Written as CVA21/pembrolizumab
- CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)CompletedPhase 1ViralyticsNCT03408587Written as CVA21
- Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)CompletedPhase 1ViralyticsNCT02565992Written as CAVATAK
- Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)CompletedPhase 1ViralyticsNCT02307149Written as CAVATAK
- Pembrolizumab + CVA21 in Advanced NSCLCStatus unknownPhase 1Olivia Newton-John Cancer Research InstituteNCT02824965Written as CVA21
- A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)TerminatedPhase 1ViralyticsNCT00832559Written as CVA21
- CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)CompletedPhase 2ViralyticsNCT01636882Written as CVA21
- A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )CompletedPhase 2ViralyticsNCT01227551Written as Coxsackievirus A21 (CVA21)
- Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)CompletedPhase 1ViralyticsNCT00636558Written as CVA21
- A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)CompletedPhase 1ViralyticsNCT00438009Written as Coxsackievirus A21
- Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)CompletedPhase 1ViralyticsNCT00235482Written as Coxsackievirus A21
Given in every arm · 2 — Gebasaxturev is usual care beside what is tested
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04303169Written as Gebasaxturev
- CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)CompletedPhase 1ViralyticsNCT02316171Written as CVA21
Codes
What other systems call Gebasaxturev · ClinicalTrials.gg INT014844
- UNII (FDA) 4B57CWT710GEBASAXTUREVOne source FDA
- RxNorm 2591813One source FDA
- NCI Thesaurus C61493GebasaxturevOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4B57CWT710 | GEBASAXTUREV | One source FDA |
| RxNorm | 2591813 | — | One source FDA |
| NCI Thesaurus | C61493 | Gebasaxturev | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.